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Genome-wide association (GWA) studies have greater power to detect genetic variants that confer modest disease risks than linkage analysis, even when testing large number of markers across the genome.
1 GWA aims at identifying the "genetic architecture" of complex diseases, which often result from the interplay of multiple genetic and environmental risk factors. 2 However, in stark contrast to the notion of "multiple factor-complex diseases", currently all published GWA studies only list 20-50 most significant SNPs and their neighboring genes (the "most significant SNPs/genes" approach), while paying little attention to the rest. Although such a simple approach has led to the discovery of novel genes for several complex diseases, there are certain limitations. First, genetic variants that confer small disease risks are likely missed in the "most significant SNPs/genes" approach after adjustment of multiple testing. Second, even those variants that confer larger effect might not always rank among the top 20-50 among hundreds of thousands of markers tested, especially when sample size is small. 3 Although it is common to report the most significant results, in many situations, researchers might formally assign weights to the SNPs according to their biological plausibility. For example, it has been proposed to incorporate information on genome-wide linkage, 4 prior belief on plausibility of positive findings, 5 or prior probability of disease association, 6 to assign weights to SNPs in GWA studies.
Simulations demonstrated that such weighted analyses can improve the power of detecting association when the weights are appropriately assigned. However, in many cases prior linkage information is not available or does not replicate for complex diseases, and the assignment of a priori probability of association is often arbitrary. Here we demonstrate that pathway-based approaches, which jointly consider multiple variants in interacting or related genes, might 4 complement the "most significant SNPs/genes" approach for interpreting GWA data on complex diseases.
Our proposed approach to the analysis of GWA data is motivated by pathway-based methods of microarray data analysis. When comparing expression profiles of different physiological states, tens or hundreds of genes may have subtle differences in expression levels. Rather than focusing on individual genes having the strongest evidence of differential expression, these pathwaybased approaches typically rank all genes by their significance of differential expression, and then look for whether a particular group of genes is enriched at one end of the ranked list more than would be expected by chance. 7 Application of pathway-based approaches in microarray data analysis often yields biological insights that are otherwise undetectable by focusing only on genes with the strongest evidence of differential expression. For example, when comparing expression levels of 22,000 genes in a microarray study on diabetes, no single gene shows statistically significant expression difference after adjustment of multiple testing; however, a pathway-based approach is capable of identifying a set of PGC-1α-responsive genes that show modest but consistent change of expression levels in muscle samples from diabetic subjects. 8 We propose that pathway-based approaches can be also applied to GWA studies on complex diseases, where multiple genes in the same pathway contribute to disease etiology, but common variations in each of these genes have modest contribution to disease risk. Rather than focusing on a few SNPs/genes with the strongest evidence of disease association, by considering multiple contributing factors together, we can potentially improve the power to detect causal pathways and disease mechanisms. To carry out pathway-based analysis on GWA data, we modified a pre-existing algorithm, the Gene Set Enrichment Analysis (GSEA) algorithm. 9 The GSEA algorithm was originally developed for microarray data analysis, and it performs especially well for situations where subtle effects of many genes contribute to changes in overall gene expression patterns. In our 10 that reflects the overrepresentation of genes within the set S at the top of the entire ranked list of genes in the genome,
and p is a parameter that gives higher weight to genes with extreme statistic values. When p = 0, this test statistic reduces to a regular Kolmogorov-Smirnov statistic, which identifies groups of genes whose r j distribution differs from that of a random gene set. 10 The authors of the original GSEA algorithm recommend using p = 1 and we followed this 
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The calculation of ES(S) relies on the maximum statistic within each gene. For genes with larger number of SNPs, the maximum statistic will be bigger than genes with smaller number of SNPs.
To adjust for gene size, we conducted a two-step correction procedure. In the first step, we permuted the disease labels of all samples ensuring the same number of individuals in each phenotype group for case-control studies; alternatively, the transmitted/un-transmitted alleles can be shuffled. During each permutation (denoted by π), we repeated the calculation of enrichment score as described above, except that the disease phenotypes were obtained from permutation.
We denote the corresponding enrichment score by ES(S, π). The purpose of this step is to calculate the ES(S, π) values for all gene sets S and all permutations π. In the second-step, we
calculated normalized enrichment score (NES), defined as (ES(S)-mean(ES(S, π))) / SD(ES(S, π)),
so that different gene sets are directly comparable to each other. The original GSEA algorithm 12 We note that the findings from this study are highly discordant from another GWA study on PD, 13 in that none of the most significant genes or even their cytogenetic positions overlap with each other. The apparent discordance between two similar GWA studies underscores the importance of looking beyond "most significant SNPs/genes" and searching for additional risk factors with moderate statistical significance. Our analysis of their data set used 390K SNPs that pass the initial quality control threshold (defined as minor allele frequency higher than 0.05, and Hardy-Weinberg equilibrium P-value 14 higher than 0.001). Using a recent human genome assembly (NCBI 36, Oct 2005) and gene structure annotation from the Ensembl database (version 42, Dec 2006), 15 we associated SNPs with their closest protein-coding genes within 500Kb. We used several different resources to construct a database of gene sets/pathways.
We first retrieved 260 annotated pathways from the BioCarta database and 190 annotated pathways from the KEGG database. 16 Next, we downloaded the Gene Ontology (GO) annotation files for human genes from the GO consortium website. 17 We processed the GO annotation file 9 and constructed 2,077 gene sets based on GO level 4 annotations in Biological Process and Molecular Function. In the GO hierarchy, one node may descend from several ancestral nodes by different paths, and we excluded those GO level 4 nodes that also occur in level 2 and 3 from our constructed gene sets. Genes whose GO annotations are in level 5 or lower of the hierarchy are assigned to their ancestral GO annotations in level 4. To reduce the multiple testing issue and to avoid testing overly narrow or broad functional categories, in our analysis, we only tested gene sets/pathways that contain at least 20 but at most 200 genes represented by markers in a given GWA data set.
Due to the extreme computational complexity of both permutation-based association tests and modified GSEA algorithm, we only used 1,000 permutation cycles to adjust for multiple hypothesis testing. After application of our algorithm to the Fung et al data set, 12 we identified two significantly enriched gene sets/pathways, including the UDP-glycotransferase pathway and the O-glycan biosynthesis pathway ( Table 1) . These two pathways are compiled from the GO database and KEGG database, respectively; they are functionally related and contain 19
overlapping genes. The finding that two glycan-related gene sets/pathways rank high in our pathway-based analysis is quite interesting: the relationship between glycobiology and neurodegenerative diseases has only been postulated and recognized in the last a few years.
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We note that the GALNT3 (MIM 601756) gene shared in these two pathways has been reported as one of the most significant genes in another GWA study on PD, 13 although the most significant SNPs around GALNT3 in Fung et al has P-value of only 0.22. These results suggest that our approach identified a potential disease susceptibility mechanism for PD, and generated 
and then calculates ES(S, π) and NES(S, π)
statistic to adjust for multiple testing. Compared to the approach that we propose previously, this "pre-ranked" module of GSEA eliminates the need for phenotype shuffling and the requirement for using raw genotype data, making it potentially attractive in many cases.
Since the pre-ranked module of GSEA requires using a single P-value to represent the significance of each gene, we tested two alternative approaches to achieve this goal. The first approach assigns the most significant P-value from all SNPs surrounding the gene to the gene.
This approach introduces biases so that larger genes are likely to have more significant P-values, and enrichment statistics for pathways containing large genes will be inflated. The second approach applies a Simes method [22] [23] [24] and computes a P-value from multiple SNPs. it is still an over-conservative approach that might lead to loss of power. We applied these two approaches to the Fung et al data set on PD and two additional GWA data sets for which only Pvalues for SNPs (but not raw genotypes) are available.
Application of the first approach produced biologically plausible signals on multiple data sets ( Table 2 ). When applied to Fung et al data set on PD, it identified a few pathways reaching statistical significance. The top gene set/pathway (glutamate receptor) is a well known PD susceptibility pathway and has been implicated in PD therapy. 25, 26 We next analyzed another GWA study on PD by Maranganore et al 13 , and found that the glutamate pathway ranks as the 3 rd best pathway. Finally, we also tested the first approach on an age-related macular degeneration (AMD [MIM 603075]) GWA dataset 27 from the dbGAP database, and found that the most significant pathways for this study are the CFH (MIM 134370)-related pathway and the ABC transporters pathway. Indeed, the association between CFH and AMD has been consistently replicated after initial publication, and AMD is one of the most common genetic diseases that have been associated with defects in ABC transporters. 28 However, after application of the second approach with Simes adjustment, the enrichment signals disappeared for all three data sets, indicating severe loss of power. Therefore, we caution that pathway-based methods using unadjusted "pre-ranked" list of genes are biased, and more powerful solution for condensing P-values from multiple SNPs into a single value is needed.
Our results demonstrate that pathway-based approaches may incorporate information from markers with moderate significance levels and may potentially detect novel disease susceptibility mechanisms in GWA studies. The identified "most significant pathways" may help formulate 12 new hypotheses or substantiate existing hypotheses, and genes that rank high in candidate pathways can serve as candidates for further replication and functional studies.
The current understanding of human gene function is incomplete, so the curated gene sets/pathways are not a comprehensive representation of functionally related gene cohorts in the human genome. One advantage of our current approach is that we used annotations from the GO database to supplement our pathway collections. The GO database contains large amounts of electronic annotations based on studies of human orthologs or paralogs in model organisms, so that we can incorporate computationally predicted gene sets/pathways in the gene enrichment analysis to improve power. Nevertheless, a large number of genes in the human genome are uncharacterized or poorly characterized so that there may not be any pathway information available. Information on SNPs near these genes will not be incorporated in the pathway-based approaches, so our approach can complement but not replace the single-SNP approach.
The modified GSEA algorithm operates on the maximum statistic among all SNPs both surrounding and within a gene, and then combines the effects of genes within the same pathway through the Kolmogorov-Smirnov-like running sum statistic on the maximum statistic of each gene, therefore increases the chance of identifying genetic variants that have modest contribution to disease risk. This pathway-based approach is inherently different from the "best SNPs/genes" approach, which operates on all SNPs in the entire genome and ignores the "joint effect" for genes in the same pathway. To adjust for the effect of different gene sizes, we employed a twostep permutation-based procedure, which preserves the type I error rate across genes of different sizes. We note that larger genes might suffer more from power loss than smaller genes. 
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We recognize that the maximum statistic is only one way to summarize association signals in a gene. When multiple distinct variants in the gene contribute to the overall association signal, the maximum statistic may no longer be the best statistic to capture such information. As discussed in our description of methodology, there has not been a widely agreed and accepted theory on how to combine test statistics on multiple SNPs into one single P-value. Genes vary greatly in their sizes and their structures of LD blocks, so any method for combining P-values may only work effectively on some genes but not others. Our own experience shows that generally if several SNPs in the same gene have higher significance levels than other SNPs in the same genomic region, they are either located in the same LD block, or in the same copy number variation (CNV) region (in many cases HWE filtering criteria is not able to exclude CNV regions from GWA analysis). Therefore, although there are numerous cases where rare variants in different parts of the same gene may lead to the same or similar disease phenotype, generally only one or very few LD blocks in a gene will harbor common causal variants. These observations support our use of maximum statistics together with permutation procedure to adjust for gene sizes. However, we note that once significant pathways are identified, it is possible to use multi-marker methods for testing marker-marker or even gene-gene interactions within the same pathway, for example, by the sum statistics for multiple markers. SNPs causing coding change or SNPs in conserved genomic regions, or arrays supplemented with dense markers in prior linkage regions). The bias in coverage may influence the prior likelihood of detecting associated variants for different genes, and may favor some gene sets/pathways rather than others. For these reasons, we caution that pathway-based approaches may work better on marker sets selected on the basis of genome-wide LD structure than custommade genotyping arrays.
Constructed gene sets/pathways may be dependent on each other or correlate with each other.
Cellular components and molecules do not work in isolation; instead pathways overlap, so that many gene sets/pathways will unavoidably share the same genes. The overlap of genes among gene sets/pathways will not affect their relative ranking of normalized enrichment statistics;
however, due to the permutation procedure for multiple hypothesis adjustment, dependent pathways will lead to decreased power (in terms of both FDR and FWER), if the causal genes are shared by multiple pathways.
Our modified GSEA algorithm preserves correlation structures between SNPs when permuting the data, and therefore can potentially increase the power of detecting association than approaches that ignores such correlation. We note that the pathway-based method does not take gene-gene correlation into account. While this might be a serious issue in microarray data analysis, it is less of a concern in GWA studies, in which genes in the same pathway may be dependent on each other only if they overlap with the same LD block or if there are epistatic interactions between them. In these cases, the contribution of genes to test statistics may be correlated and potentially lead to over-estimation of significance of pathways.
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In conclusion, our results demonstrate the applicability of pathway-based approaches in the interpretation and analysis of GWA data. We hope to encourage the community to look beyond the "tip of the iceberg" (most significant SNPs/genes) for GWA on complex diseases. The development of pathway-based approaches that incorporate and weigh prior biological knowledge, including those gleaned from model organisms, will greatly facilitate the interpretation of GWA data and will lead to the identification of novel disease susceptibility genes and mechanisms. 
